Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal 7-valent conjugate vaccine + pneumococcal 13-valent conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a combination of two pneumococcal conjugate vaccines. Prevenar (7-valent) was the earlier version containing 7 serotypes of Streptococcus pneumoniae, while Prevenar 13 is the newer version containing 13 serotypes (including the original 7 plus 6 additional serotypes). The vaccines help prevent pneumococcal disease including pneumonia, meningitis, bacteremia, sepsis and acute otitis media. Children who began immunization with Prevenar (7-valent) may complete their vaccination schedule by switching to Prevenar 13 at any point in the schedule. For children 12-59 months who are completely immunized with Prevenar (7-valent), a single dose of Prevenar 13 is recommended to elicit immune responses to the 6 additional serotypes, administered at least 8 weeks after the final dose of Prevenar (7-valent).
- Brand names
- Prevenar + Prevenar 13Prevnar + Prevnar 13
- Other names
- pneumococcal 7-valent conjugate vaccine + pneumococcal 13-valent conjugate vaccine
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on pneumococcal 7-valent conjugate vaccine + pneumococcal 13-valent conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal 7-valent conjugate vaccine + pneumococcal 13-valent conjugate vaccine.